Dosed first patients in a key wound care trial and expects interim results in 2H 2026. R&D expenses declined year-over-year, net loss was $4.1M, and cash totaled $3.5M. Raised $12M in new financing and expanded patent portfolio.Original document: FibroBiologics, Inc. [FBLG] SEC 8-K Current Report —…
FibroBiologics, Inc. reported a net loss of $(4.12M) for the quarter ended 2Q 2026, compared with a net loss of $(4.66M) in the year-ago quarter; the company remains pre-revenue with no product sales reported for the period.Financial HighlightsBusiness HighlightsOriginal SEC Filing: FibroBiologics…
On July 22, 2026, Nasdaq notified the company that it determined to delist its securities from The Nasdaq Capital Market after the bid price stayed below $1.00 for 30 consecutive business days, and the company is ineligible for a 180-day cure period due to a recent reverse split. Unless appealed by…
FBLG (FibroBiologics, Inc.) is set to announce its Q2'26 results on July 30, time not specified. The earnings are expected to be disclosed at 8:00 AM ET (12:00 PM UTC).For Q2'26, revenue estimate is 0 USD with EPS (earnings per share) anticipated at (0.93) USD. Learn more details at FBLG Financials…
FibroBiologics closed a $3.0 million private placement, issuing pre-funded warrants for up to 4,081,633 shares and short-term and long-term warrants totaling 8,163,266 shares at a $0.735 exercise price, subject to stockholder approval. Net proceeds were about $2.6 million, intended for working capi…
$3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrantsHOUSTON, June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ pate…
